DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/22a5735e/colombia_pharmaceu) has announced the addition of the "Colombia Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
Business Monitor International's Colombia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Colombia's pharmaceuticals and healthcare industry.
Colombia's pharmaceutical and healthcare markets will perform better than the regional average over the medium term due to its high urbanisation rate and population growth. Strong macroeconomic growth will be the fundamental driving force for behind this expansion. BMI expect the gradually improving intellectual property (IP) regulatory framework and increasing medical coverage among the population to increase the country's attractiveness to the multinational pharmaceutical companies.
Key Trends And Developments
- In January 2012, Patheon, a Canada-based multinational company providing contract dosage form development and manufacturing services to the pharmaceutical and biotechnology industries, signed an agreement with Procaps, a Colombia-based soft gelatine capsule manufacturer, to increase its global soft gel production capacity.
- Faes Farma and Laboratorios Salvat, two Spanish pharmaceutical companies, signed a longterm agreement for Faes Farma to market three of Salvat's products in Argentina, Venezuela, Colombia, Chile and Paraguay, where Faes Farma already has a direct commercial presence.
- Patients Colombia, a group of 146 patient organisations, asked the government to regularise biotech drugs in the country in January 2012.
- Colombia became the first country in the western hemisphere to eliminate river blindness disease (onchocerciasis) in November 2011, the Pan-American Health Organization (PAHO) said.
- In November 2011, police said prescription drug abuse presents the biggest hurdle in the country's fight against drug cartels.
- The government announced a plan for additional tax benefits for people aged 60 and over on contributory and subsidised health benefits in November 2011.
Companies Mentioned
- Tecnoqu?micas
- Lafrancol
- Laboratorios Genfar SA
- Laboratorios Brussi?
- GlaxoSmithKline
- Pfizer
- Merck & Co
- Sanofi
- Novartis
For more information visit http://www.researchandmarkets.com/research/22a5735e/colombia_pharmaceu